Literature DB >> 9824497

The role of neutralizing antibody and T-helper subtypes in protection and pathogenesis of vaccinated mice following ocular HSV-1 challenge.

H Ghiasi1, S L Wechsler, S Cai, A B Nesburn, F M Hofman.   

Abstract

In order to determine the possible correlation of specific immune responses with protection against mortality and ocular disease following ocular herpes simplex virus type 1 (HSV-1) challenge, BALB/c mice were vaccinated with different doses and regimens of baculovirus-expressed gD. Neutralizing antibody, virus titres in the eyes, corneal scarring, and survival were measured. In addition, infiltration into the cornea of CD4+ T cells and cells containing the lymphokines interleukin-2 (IL-2), IL-4, IL-6 and tumour necrosis factor-alpha (TNF-alpha) were monitored on days 3, 7, 10, 14 and 21 post-challenge by immunocytochemistry. The vaccination regimens used induced varying degrees of immune responses and protection upon ocular challenge with HSV-1. Our results suggest that neutralizing antibody was the most important immune response in protecting mice against lethal ocular challenge and corneal scarring. TNF-alpha and IL-2 were not crucial in terms of survival and corneal scarring, since gD1 (one vaccination with 1 microg of gD) and gD0.1 (one vaccination with 0.1 microg of gD), both of which provided high levels of protection, showed no TNF-alpha or IL-2 expression. However, TNF-alpha and IL-2 were crucial in terms of virus clearance from the eyes, since gD3 (three vaccinations with 1 microg of gD), which had less virus in their eyes, had high numbers of TNF-alpha and IL-2 infiltrates. Finally, mock-vaccinated mice were not protected from death and corneal disease following HSV-1 challenge. Eyes of mock-vaccinated mice had little or no TNF-alpha or IL-2 responses and the strongest IL-4 and IL-6 responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824497      PMCID: PMC1364400          DOI: 10.1046/j.1365-2567.1998.00602.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  35 in total

Review 1.  Recurrence in ocular herpes simplex infection.

Authors:  A B Nesburn
Journal:  Int Ophthalmol Clin       Date:  1975

2.  Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells.

Authors:  E Manickan; S Kanangat; R J Rouse; Z Yu; B T Rouse
Journal:  J Leukoc Biol       Date:  1997-02       Impact factor: 4.962

Review 3.  Ocular herpes simplex virus infections.

Authors:  C R Dawson
Journal:  Clin Dermatol       Date:  1984 Apr-Jun       Impact factor: 3.541

4.  Herpes simplex virus isolation in chronic stromal keratitis: human and laboratory studies.

Authors:  D L Easty; C Shimeld; C M Claoue; M Menage
Journal:  Curr Eye Res       Date:  1987-01       Impact factor: 2.424

5.  Contribution of virus and immune factors to herpes simplex virus type I-induced corneal pathology.

Authors:  R L Hendricks; T M Tumpey
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-10       Impact factor: 4.799

6.  Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system.

Authors:  C Shimeld; T J Hill; W A Blyth; D L Easty
Journal:  J Gen Virol       Date:  1990-03       Impact factor: 3.891

7.  Fine mapping of the major latency-related RNA of herpes simplex virus type 1 in humans.

Authors:  S L Wechsler; A B Nesburn; R Watson; S Slanina; H Ghiasi
Journal:  J Gen Virol       Date:  1988-12       Impact factor: 3.891

8.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Authors:  T R Mosmann; H Cherwinski; M W Bond; M A Giedlin; R L Coffman
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

9.  Herpetic stromal keratitis-evidence for cell-mediated immunopathogenesis.

Authors:  J F Metcalf; H E Kaufman
Journal:  Am J Ophthalmol       Date:  1976-12       Impact factor: 5.258

10.  Evidence for mouse Th1- and Th2-like helper T cells in vivo. Selective reduction of Th1-like cells after total lymphoid irradiation.

Authors:  H Bass; T Mosmann; S Strober
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more
  21 in total

1.  Immunization with different viral antigens alters the pattern of T cell exhaustion and latency in herpes simplex virus type 1-infected mice.

Authors:  Sariah J Allen; Kevin R Mott; Mandana Zandian; Homayon Ghiasi
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

2.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?"

Authors:  Derek J Royer; Daniel J J Carr
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

4.  Roles of M1 and M2 Macrophages in Herpes Simplex Virus 1 Infectivity.

Authors:  Dhong Hyun Lee; Homayon Ghiasi
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

5.  Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.

Authors:  Yanira Osorio; Homayon Ghiasi
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  The expression of IL-2 and IL-4 in CD4(+) T cells from mouse lymph nodes and spleen during HSV-1-induced facial palsy.

Authors:  Lintao Gu; Yuechen Han; Wenwen Liu; Yanyan Mao; Jianfeng Li; Haibo Wang
Journal:  Inflamm Res       Date:  2013-11-27       Impact factor: 4.575

7.  Exacerbation of corneal scarring in HSV-1 gK-immunized mice correlates with elevation of CD8+CD25+ T cells in corneas of ocularly infected mice.

Authors:  Sariah J Allen; Kevin R Mott; Alexander V Ljubimov; Homayon Ghiasi
Journal:  Virology       Date:  2010-01-18       Impact factor: 3.616

8.  Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice.

Authors:  C M Richards; R Case; T R Hirst; T J Hill; N A Williams
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.

Authors:  Derek J Royer; Hem R Gurung; Jeremy K Jinkins; Joshua J Geltz; Jennifer L Wu; William P Halford; Daniel J J Carr
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

10.  Involvement of STAT4 in IgG subtype switching and ocular HSV-1 replication in mice.

Authors:  Sariah J Allen; Kevin R Mott; Homayon Ghiasi
Journal:  Mol Vis       Date:  2010-01-26       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.